Latest News for: tnx

Edit

TNX 102 SL for Lead Indication: Fibromyalgia Additional Indication: Acute Stress Disorder (Tonix Pharmaceuticals Holding Corp)

Public Technologies 14 Jan 2025
TNX-102 SL ... TNX-102 SL ... TNX-1300 ... TNX-2900 ... TNX-1500 ... TNX-102 SL* ... *5.6 mg once-daily at bedtime, TNX-102 SL is an investigational new drug, its efficacy and safety have not been established and it has not been approved for any ... TNX-102 SL.
Edit

Biomednewsbreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awaits FDA Decision On TNX-102 SL For Fibromyalgia

MENA FN 24 Dec 2024
(MENAFN - Investor Brand Network). Tonix Pharmaceuticals (NASDAQ. TNXP) announced that the FDA has set a Prescription Drug User Fee Act (–PDUFA–) goal date of Aug. 15, 2025, for a decision on ... .
Edit

Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX 102 SL for Fibromyalgia Form 8 K (Tonix Pharmaceuticals Holding Corp)

Public Technologies 23 Dec 2024
Marketing Approval for TNX-102 SL for Fibromyalgia. Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 ... TNX-102 SL is a non-opioid, centrally-acting analgesic ... About TNX-102 SL.
Edit

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

Nasdaq Globe Newswire 17 Dec 2024
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74 Letter ... .
Edit

FDA accepts Tonix’s NDA for non-opioid fibromyalgia drug TNX-102 SL

Invezz 17 Dec 2024
TNXP) announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for TNX-102 SL, a non-opioid, centrally acting analgesic designed for fibromyalgia management.
Edit

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX 102 SL for Fibromyalgia Form 8 K (Tonix Pharmaceuticals Holding Corp)

Public Technologies 17 Dec 2024
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia ... TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA ... About TNX-102 SL.
Edit

Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers

ACCESSWIRE 09 Dec 2024
Food and Drug Administration (FDA) in October for TNX-102 SL (cyclobenzaprine HCl sublingual tablets), Tonix's drug candidate for the management of fibromyalgia ... The FDA previously granted TNX-102 SL ...
Edit

TNX-102 SL for Lead Indication: Fibromyalgia Additional Indication: Acute Stress Disorder (Tonix Pharmaceuticals Holding Corp)

Public Technologies 04 Dec 2024
). TNX-102 SL. Lead Indication. Fibromyalgia. Additional Indication. Acute Stress Disorder. NASDAQ. TNXP. December 2024. PO6027 December 3, 2024 (Doc 1539) ... TNX-102 SL*. Cyclobenzaprine HCl ... Differentiators. ... *TNX-102 SL has not been approved for any indication.
Edit

TNX-1500 for Organ Transplant Rejection & Autoimmune Disorders (Tonix Pharmaceuticals Holding Corp)

Public Technologies 04 Dec 2024
TNX-1500 ... TNX-1500* ... Third Generation (TNX-1500) ... *TNX-1500 has not been approved for any indication ... TNX-1500 (anti-CD40L) for Organ Transplant ... TNX-1500 Preclinical Data and Publications ... TNX-1500 (-CD40 Ligand) ... TNX-1500.
Edit

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the ...

Nasdaq Globe Newswire 18 Nov 2024
Poster presentation highlighted results from confirmatory ...
Edit

Tonix Pharmaceuticals Announces Peer Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single Dose Mpox and Smallpox Vaccine Candidate TNX 801, in Immune Compromised Animals Form 8 K (Tonix Pharmaceuticals Holding Corp)

Public Technologies 13 Nov 2024
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals ... About TNX-801*.
Edit

Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX 801 for Mpox in Kenya Form 8 K (Tonix Pharmaceuticals Holding Corp)

Public Technologies 04 Nov 2024
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya ... About TNX-801*.
Edit

Tonix Pharmaceuticals Presented Data On Potential Mpox Vaccine TNX-801 At World Vaccine Congress-Europe 2024

MENA FN 01 Nov 2024
(MENAFN - GlobeNewsWire - Nasdaq) New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix's attenuated live-virus, minimally replicating vaccine ... .
Edit

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX 801 at World Vaccine Congress Europe 2024 Form 8 K (Tonix Pharmaceuticals Holding Corp)

Public Technologies 01 Nov 2024
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 ... About TNX-801* ... TNX-1800 is an engineered version of horsepox that expresses the spike protein of SARS-CoV-2.
Edit

TNX’s Kyungjun to leave K-pop boy band, to serve mandatory military service

India TV 23 Oct 2024
The official page of the K-pop band TNX shared the news on their social media handles.

Article Search

tools

Most Viewed

×
×
×
×